Servier sees 4.5% sales growth for 2017/18

French privately-held drugmaker Servier today announced that group’s sales for the 2017-2018 financial year were 4.2 billion euros ($4.8 billion), a year-on-year rise of 4.5%.

This figure notably results from an 8% increase in the volume of sales of its drugs, attenuated by unfavorable effects of pricing and foreign currency rates, due to Servier’s strong presence outside the eurozone, and by patent expiries, notably in Canada and in all countries for Procoralan (ivabradine). This explains that at the real exchange rate, sales growth was 0.6%.

Operating income for 2017-2018 was 435 million euros, a rise of nearly 42%. Earnings before interest, taxes, depreciation and amortization (EBITDA) came in at 623 million euros, up 55%.